Screener
Biogen BIIB Common Stock Par Value Per Share
Common Stock Par Value Per Share at other companies
Other financials
Where this comes from
Reported directly by Biogen in its filing.
Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.
The source filing: Biogen’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 6:36 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000875045-26-000075
| Line item | As of June 30, 2026 | As of December 31, 2025 |
|---|---|---|
| Equity: | ||
| Biogen Inc. shareholders’ equity: | ||
| Preferred stock, par value $0.001 per share | — | — |
| Common stock, par value $0.0005 per share | 0.1 | 0.1 |
| Additional paid-in capital | 983.0 | 863.1 |
| Accumulated other comprehensive income (loss) | (127.7) | (182.0) |
| Retained earnings | 20,969.7 | 20,552.7 |
| Treasury stock, at cost | (2,977.1) | (2,977.1) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Biogen's common stock par value per share?
- Biogen (BIIB) reported common stock par value per share of $0.00 in Q2 2026.
- How has Biogen's common stock par value per share changed year-over-year?
- Biogen's common stock par value per share decreased by 0.0% year-over-year, from $0.00 to $0.00.
- What is the long-term trend for Biogen's common stock par value per share?
- Over 3 years (2020 to 2023), Biogen's common stock par value per share has grown at a 0.0% compound annual growth rate (CAGR), from $0.00 to $0.00.
- What does common stock par value per share mean?
- The par value of common stock is the arbitrary legal value assigned to each share of common stock at the time of issuance. It is a legacy accounting requirement that has little impact on the actual market value or trading price of the shares.
Ask your AI about Biogen's common stock par value per share.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude